Clinical Trial Results:
Tocotrienol as a nutritional supplement in patients with advanced pulmonal cancer
Summary
|
|
EudraCT number |
2015-002742-32 |
Trial protocol |
DK |
Global end of trial date |
09 May 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
10 Apr 2021
|
First version publication date |
10 Apr 2021
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
Toco-Pulm
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT02644252 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Vejle Hospital
|
||
Sponsor organisation address |
Beriderbakken 4, Vejle, Denmark,
|
||
Public contact |
Clinical Trial Unit, Vejle Hospital, kfe.onko@rsyd.dk
|
||
Scientific contact |
Clinical Trial Unit, Vejle Hospital, kfe.onko@rsyd.dk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 May 2020
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
09 May 2019
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The main objective is to investigate the effect of tocotrienol as a nutritional supplement in combination with first-line chemotherapy on progression free survival (PFS) in patients with advanced NSCLC
|
||
Protection of trial subjects |
Anti-emetics and analgesics administered as needed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
05 Feb 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Denmark: 78
|
||
Worldwide total number of subjects |
78
|
||
EEA total number of subjects |
78
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
27
|
||
From 65 to 84 years |
51
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
Danish patients with advanced non-small cell lung cancer recruited in the outpatient setting. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Patients with locally advanced non-small cell lung cancer were screened on an outpatient basis. | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
Overall trial (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Standard treatment + placebo | ||||||||||||||||||
Arm description |
Combination chemotherapy with platinum | ||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||
Investigational medicinal product name |
Cisplatin
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Concentrate and solvent for solution for infusion
|
||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||
Dosage and administration details |
Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2
|
||||||||||||||||||
Arm title
|
Standard treatment + tocotrienol | ||||||||||||||||||
Arm description |
Combination chemotherapy with platinum + tocotrienol | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Tocotrienol
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Capsule, soft
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Daily: Tocotrienol 300 mg x 3
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Overall trial
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Arm A, standard + placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients with advanced lung cancer receiving standard chemotherapy + placebo
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Arm B, standard + tocotrienol
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Patients with advanced lung cancer receiving standard chemotherapy + tocotrienol
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Standard treatment + placebo
|
||
Reporting group description |
Combination chemotherapy with platinum | ||
Reporting group title |
Standard treatment + tocotrienol
|
||
Reporting group description |
Combination chemotherapy with platinum + tocotrienol | ||
Subject analysis set title |
Arm A, standard + placebo
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Patients with advanced lung cancer receiving standard chemotherapy + placebo
|
||
Subject analysis set title |
Arm B, standard + tocotrienol
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Patients with advanced lung cancer receiving standard chemotherapy + tocotrienol
|
|
|||||||||||||
End point title |
Progression free survival [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
From date of randomization to progression
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The trial was ended prematurely because of a poor accrual rate |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||
Adverse events information [1]
|
|||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Before start of each treatment cycle, i.e. every three weeks.
|
||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
AEs graded according to CTCAE version 4.0
|
||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | ||||||||||||||||||||||||||||||||||||||
Dictionary version |
4
|
||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||
Reporting group title |
Toxicity
|
||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: The frequency of each non-serious event was below the 5% cut-off. |
|||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |